Calcifediolum [Inn-Latin] en es it fr

Calcifediolum [Inn-Latin] Brand names, Calcifediolum [Inn-Latin] Analogs

Calcifediolum [Inn-Latin] Brand Names Mixture

  • No information avaliable

Calcifediolum [Inn-Latin] Chemical_Formula


Calcifediolum [Inn-Latin] RX_link

No information avaliable

Calcifediolum [Inn-Latin] fda sheet

Calcifediolum [Inn-Latin] msds (material safety sheet)

Calcifediolum [Inn-Latin] Synthesis Reference

Blunt, DeLuca, ibid. 8, 671.

Calcifediolum [Inn-Latin] Molecular Weight

400.637 g/mol

Calcifediolum [Inn-Latin] Melting Point

No information avaliable

Calcifediolum [Inn-Latin] H2O Solubility


Calcifediolum [Inn-Latin] State


Calcifediolum [Inn-Latin] LogP


Calcifediolum [Inn-Latin] Dosage Forms


Calcifediolum [Inn-Latin] Indication

Used to treat vitamin D deficiency or insufficiency, refractory rickets (vitamin D resistant rickets), familial hypophosphatemia and hypoparathyroidism, and in the management of hypocalcemia and renal osteodystrophy in patients with chronic renal failure undergoing dialysis. Also used in conjunction with calcium in the management and prevention of primary or corticosteroid-induced osteoporosis.

Calcifediolum [Inn-Latin] Pharmacology

Calcidiol is a form of vitamin D3. Vitamin D3 is a steroid hormone that has long been known for its important role in regulating body levels of calcium and phosphorus, in mineralization of bone, and for the assimilation of Vitamin A. The classical manifestations of vitamin D deficiency is rickets, which is seen in children and results in bony deformaties including bowed long bones. Deficiency in adults leads to the disease osteomalacia. Both rickets and osteomalacia reflect impaired mineralization of newly synthesized bone matrix, and usually result from a combination of inadequate exposure to sunlight and decreased dietary intake of vitamin D. Common causes of vitamin D deficiency include genetic defects in the vitamin D receptor, severe liver or kidney disease, and insufficient exposure to sunlight. Vitamin D plays an important role in maintaining calcium balance and in the regulation of parathyroid hormone (PTH). It promotes renal reabsorption of calcium, increases intestinal absorption of calcium and phosphorus, and increases calcium and phosphorus mobilization from bone to plasma.

Calcifediolum [Inn-Latin] Absorption

Readily absorbed.

Calcifediolum [Inn-Latin] side effects and Toxicity

Bone pain, constipation (especially in children or adolescents), diarrhea, drowsiness, dryness of mouth; headache (continuing), increased thirst, increase in frequency of urination, especially at night, or in amount of urine, irregular heartbeat, itching skin, loss of appetite, metallic taste, muscle pain, nausea or vomiting (especially in children or adolescents), unusual tiredness or weakness.

Calcifediolum [Inn-Latin] Patient Information

Patient information for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol):

The patient and his or her parents or s.o.s. should be informed about compliance with dosage instructions, adherence to instructions about diet and calcium supplementation and avoidance of the use of unapproved nonprescription drugs. Patients should also be carefully informed about the symptoms of hypercalcemia.

The effectiveness of vitamin D therapy is predicated on the assumption that each patient is receiving an adequate daily intake of calcium. Patients are advised to have a dietary intake of calcium at a minimum of 600 mg daily. The U.S. RDA for calcium in adults is 800 mg to 1200 mg.

Calcifediolum [Inn-Latin] Organisms Affected

Humans and other mammals